Trametinib in the Treatment of Multiple Malignancies Harboring MEK1 Mutations

With the popularization of Next-generation sequencing technology, targeted cancer therapy based on gene mutations has attracted more and more attention. Aberrant activated mitogen-activated protein kinases (MAPK) pathway is considered to play a crucial role in the occurrence and development of various cancers [1]. Various mutations in pathway components including MEK1/2 can cause the aberrant activation of MAPK signaling pathway [2]. As oncogenic mutations, MEK1 mutations were widely observed in many cancers [1,3,4], while trametinib, a MEK1/2 inhibitor, was limited to treat BRAF-mutant melanoma and non-small-cell lung cancer (NSCLC) according to the approval of FDA [2,5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research